Zymeworks Inc (ZYME) FinancialsZYMEZymeworks Inc

Evaluating the bottom line, Zymeworks Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -918.95%, while the net margin is -980.81%. These profitability ratios, combined with a Return on Equity (ROE) of -72.31%, provide a clear picture of how effectively ZYME converts its operational activities into shareholder value.

In the context of the broader market, ZYME competes directly with industry leaders such as PRGO and AGIO. With a market capitalization of $2.08B, it holds a leading position in the sector. When comparing efficiency, ZYME's gross margin of 100.00% stands against PRGO's 30.69% and AGIO's 93.30%. Such benchmarking helps identify whether Zymeworks Inc. is trading at a premium or discount relative to its financial performance.

Zymeworks has shown a gross margin of 100% across recent quarters, indicating strong profitability on sales, although it has reported negative net income in the last few quarters, with a net loss of $45 million in Q2 2026.